ArticleRheumatology (Oxford, England)2025
Anxiety symptoms and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a cross-sectional study.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The mirror of illness: identity, embodiment, and clinical care in systemic sclerosis.Clinical rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
objectiveWe (1) compared anxiety symptom levels in a multinational SSc cohort to a general population normative sample and (2) evaluated sociodemographic, lifestyle and SSc disease factors associated with symptoms.
methodsScleroderma Patient-centered Intervention Network Cohort participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Version 2 4a Anxiety domain upon enrolment. PROMIS domain scores use T-scores (mean = 50, S.D. = 10) calibrated to a United States normative sample. We compared T-scores to the PROMIS United States normative sample and, in SSc, assessed associations of sociodemographic, lifestyle and physician-reported disease-related variables with multivariable linear regression.
resultsAmong 2463 participants with SSc, mean anxiety symptom T-score (52.6, S.D. = 10.0, 95% CI 52.2, 53.0) was ∼1/3 S.D. higher than the United States general population mean of 50 (S.D. = 10), though within normal limits. Higher T-scores were associated with younger age (1.07 T-score points per 10 years, 95% CI 0.74, 1.40), female sex (1.81, 95% CI 0.63, 3.00), non-married status (0.99, 95% CI 0.14, 1.84), race or ethnicity other than White (1.79, 95% CI 0.72, 2.85), living in Canada (1.70, 95% CI 0.61, 2.79), the United Kingdom (1.53, 95% CI 0.06, 2.99) or France (2.01, 95% CI 0.98, 3.03) (vs the United States), higher BMI (0.11, 95% CI 0.03, 0.17), less time since non-Raynaud's symptom onset (0.82 per 10 years, 95% CI 0.40, 1.30), gastrointestinal involvement (2.70, 95% CI 1.52, 3.88), moderate small joint contractures (1.24, 95% CI 0.10, 2.38), the absence of interstitial lung disease (0.93, 95% CI -1.79, -0.07) and Sjögren disease (1.67, 95% CI 0.17, 3.17). Interstitial lung disease was not statistically significant when accounting for an interaction with country. Anxiety was also associated with pruritus and pain intensity in a sensitivity analysis that included variables with possible bi-directional pathways with anxiety.
conclusionAnxiety symptoms were somewhat elevated among individuals with SSc and associated with multiple sociodemographic and disease factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.